127 related articles for article (PubMed ID: 23138181)
1. Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia.
Bohnstedt C; Levinsen M; Rosthøj S; Zeller B; Taskinen M; Hafsteinsdottir S; Björgvinsdóttir H; Heyman M; Schmiegelow K;
Leukemia; 2013 Apr; 27(4):866-70. PubMed ID: 23138181
[TBL] [Abstract][Full Text] [Related]
2. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
[TBL] [Abstract][Full Text] [Related]
3. Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).
Arico M; Ziino O; Valsecchi MG; Cazzaniga G; Baronci C; Messina C; Pession A; Santoro N; Basso G; Conter V;
Cancer; 2008 Aug; 113(3):515-21. PubMed ID: 18521927
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
[TBL] [Abstract][Full Text] [Related]
5. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
[TBL] [Abstract][Full Text] [Related]
6. The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.
Schmiegelow K; Heyman M; Gustafsson G; Lausen B; Wesenberg F; Kristinsson J; Vettenranta K; Schroeder H; Forestier E; Rosthoej S;
Leukemia; 2010 Apr; 24(4):715-20. PubMed ID: 20130603
[TBL] [Abstract][Full Text] [Related]
7. Acute leukaemia in children with Down syndrome: a population-based Nordic study.
Zeller B; Gustafsson G; Forestier E; Abrahamsson J; Clausen N; Heldrup J; Hovi L; Jonmundsson G; Lie SO; Glomstein A; Hasle H;
Br J Haematol; 2005 Mar; 128(6):797-804. PubMed ID: 15755283
[TBL] [Abstract][Full Text] [Related]
8. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
[TBL] [Abstract][Full Text] [Related]
9. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
[TBL] [Abstract][Full Text] [Related]
10. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome.
Shah N; Al-Ahmari A; Al-Yamani A; Dupuis L; Stephens D; Hitzler J
Pediatr Blood Cancer; 2009 Jan; 52(1):14-9. PubMed ID: 18802938
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome.
Meyr F; Escherich G; Mann G; Klingebiel T; Kulozik A; Rossig C; Schrappe M; Henze G; von Stackelberg A; Hitzler J
Br J Haematol; 2013 Jul; 162(1):98-106. PubMed ID: 23594030
[TBL] [Abstract][Full Text] [Related]
12. Poor treatment compliance in children with down syndrome and acute lymphoblastic leukemia.
Bohnstedt C; Taskinen M; Zeller B; Björgvinsdóttir H; Hafsteinsdottir S; Schmiegelow K
J Pediatr Hematol Oncol; 2009 Jan; 31(1):79-80. PubMed ID: 19125098
[No Abstract] [Full Text] [Related]
13. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
[TBL] [Abstract][Full Text] [Related]
14. Down syndrome and acute lymphoblastic leukaemia.
Whitlock JA
Br J Haematol; 2006 Dec; 135(5):595-602. PubMed ID: 17054672
[TBL] [Abstract][Full Text] [Related]
15. High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia: biological background and prognostic impact. Results from the NOPHO ALL-92 and ALL-2000 studies.
Vaitkevičienė G; Forestier E; Hellebostad M; Heyman M; Jonsson OG; Lähteenmäki PM; Rosthoej S; Söderhäll S; Schmiegelow K;
Eur J Haematol; 2011 Jan; 86(1):38-46. PubMed ID: 21077959
[TBL] [Abstract][Full Text] [Related]
16. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.
Bassal M; La MK; Whitlock JA; Sather HN; Heerema NA; Gaynon PS; Stork LC
Pediatr Blood Cancer; 2005 Jan; 44(1):21-8. PubMed ID: 15368546
[TBL] [Abstract][Full Text] [Related]
17. Acute lymphoblastic leukaemia in children with Down syndrome: an updated review.
Maloney KW
Br J Haematol; 2011 Nov; 155(4):420-5. PubMed ID: 21933171
[TBL] [Abstract][Full Text] [Related]
18. Vincristine pharmacokinetics in children with Down syndrome.
Lönnerholm G; Frost BM; Söderhäll S; de Graaf SS
Pediatr Blood Cancer; 2009 Jan; 52(1):123-5. PubMed ID: 18615507
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
Schmiegelow K; Nersting J; Nielsen SN; Heyman M; Wesenberg F; Kristinsson J; Vettenranta K; Schrøeder H; Weinshilboum R; Jensen KL; Grell K; Rosthoej S
Pediatr Blood Cancer; 2016 Dec; 63(12):2104-2111. PubMed ID: 27447547
[TBL] [Abstract][Full Text] [Related]
20. Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication.
Schrøder H; Kjeldahl M; Boesen AM; Nielsen OJ; Schmidt K; Johnsen HE; Gregersen H; Heyman M; Gustafsson G
Dan Med Bull; 2006 Feb; 53(1):76-9. PubMed ID: 16761337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]